Sex Differences in Low-Density Lipoprotein Cholesterol Reduction With PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry-Reference-Cited by-同舟云学术

Sex Differences in Low-Density Lipoprotein Cholesterol Reduction With PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

Published:2022-04 Issue:4 Volume:79 Page:523-529
ISSN:0160-2446
Container-title:Journal of Cardiovascular Pharmacology
language:en
Short-container-title:

Author:

Cordero Alberto,Fernández del Olmo M. Rosa,Cortez Quiroga Gustavo A.,Romero-Menor Cesar,Fácila Lorenzo,Seijas-Amigo José,Fornovi Aisa,Murillo Juan R.,Rodríguez-Mañero Moisés,Bello Mora María C.,Valle Alfonso,Miriam Sandin,Pamias Roman F.,Bañeras Jordi,García Pedro B.,Clemente Lorenzo Maria M.,Sánchez-Alvarez Sergio,López-Rodríguez Luis,González-Juanatey José R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference31 articles.

1. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events;Sabatine;N Engl J Med,2015

2. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events;Robinson;N Engl J Med,2015

3. Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study;Gaudet;Eur J Prev Cardiol,2021

4. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med,2017

5. Alirocumab and cardiovascular outcomes after acute coronary syndrome;Schwartz;N Engl J Med,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal Anti-PCSK9 Antibodies: Real-World Data;Journal of Clinical Medicine;2024-08-03

2. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study;Journal of Clinical Lipidology;2024-07

3. Italian Association of Hospital Cardiologists Position Paper ‘Gender discrepancy: time to implement gender-based clinical management’;European Heart Journal Supplements;2024-04

4. Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations;Current Opinion in Lipidology;2024-03-27

5. Addressing Ancestry and Sex Bias in Pharmacogenomics;Annual Review of Pharmacology and Toxicology;2024-01-23